Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33639
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarris G.M.en
dc.contributor.authorGan T.E.en
dc.contributor.authorTipping P.G.en
dc.contributor.authorVollenhoven B.J.en
dc.contributor.authorStendt C.L.en
dc.date.accessioned2021-05-14T11:23:54Zen
dc.date.available2021-05-14T11:23:54Zen
dc.date.copyright1999en
dc.date.created19990331en
dc.date.issued2012-10-19en
dc.identifier.citationAmerican Journal of Hematology. 60 (3) (pp 175-180), 1999. Date of Publication: 1999.en
dc.identifier.issn0361-8609en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/33639en
dc.description.abstractUse of combined oral contraceptives (OC) is associated with a significant risk of thrombosis. The mechanisms of this effect are not clearly defined. Tissue factor pathway inhibitor (TFPI) is a circulating anti- coagulant that inhibits the earliest steps in activation of the extrinsic coagulation pathway. It plays a central role in control of coagulation but its contribution to the thrombotic risk associated with OC has not been assessed. Plasma TFPI antigen and activity, factor VIIa, prothrombin fragments 1 and 2, von Willebrand antigen, fibrinogen, and low density lipoprotein cholesterol were measured by standard assays in women taking OC (aged 16 to 45 years, n = 40) and age-matched women not taking OC (controls, n = 40). Plasma TFPI antigen did not vary significantly across the menstrual cycle in controls. Women on OC had a 25% reduction in plasma TFPI antigen (median 51.0 ng/ml; 95% confidence intervals [CI] 37.5 to 85.5; control 68.0 ng/ml, CI 61.0 to 95.0; P< 0.001) and a 29% reduction in TFPI activity (78.5 U/ml, CI 57.5 to 107.5; control 111.0 U/ml, CI 79.5 to 171.0; P < 0.001) compared to controls. Plasma factor VIIa activity and prothrombin fragments 1 and 2 were also significantly increased in women using OC (both P < 0.001), indicating activation of the extrinsic coagulation pathway. These results demonstrate that normal cyclic variations in estrogen and/or progesterone do not significantly alter plasma TFPI levels. However, estrogens and/or progestogens in OC result in activation of the extrinsic coagulation pathway and significantly reduce plasma TFPI, its major circulating inhibitor. Reduced plasma TFPI levels may underlie the thrombotic effects of OC.en
dc.languageEnglishen
dc.languageenen
dc.publisherWiley-Liss Inc. (111 River Street, Hoboken NJ 07030-5774, United States)en
dc.titleDecreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.en
dc.typeArticleen
dc.identifier.affiliationObstetrics and Gynaecology (Monash Women's)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/%28SICI%291096-8652%28199903%2960:3%3C175en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid10072106 [http://www.ncbi.nlm.nih.gov/pubmed/?term=10072106]en
dc.identifier.source29108765en
dc.identifier.institution(Tipping) Department of Medicine, Monash Medical Centre, Block E, 246 Clayton Rd., Clayton, Vic. 3168, Australiaen
dc.description.addressP.G. Tipping, Department of Medicine, Monash Medical Centre, 246 Clayton Rd., Clayton, Vic. 3168, Australia. E-mail: peter.tipping@med.monash.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCoagulation Factor VIIa Lipoprotein Oral contraceptive Prothrombin Thrombosis Tissue factor pathway inhibitoren
dc.identifier.authoremailTipping P.G.; peter.tipping@med.monash.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Articles
Show simple item record

Page view(s)

22
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.